Investigation of the female infertility risk associated with anti-cancer therapy

Lavafian, Atiye; Pezeshki, Parmida Sadat; Rezaei, Nima

doi:10.1007/s12094-023-03087-8

Cited by 4 publications

(1 citation statement)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, the use of nonsteroidal anti-inflammatory drugs, oral contraceptives, and IUDs or the existence of some medical conditions such as polycystic ovarian syndrome, metabolic syndrome, systemic lupus erythematosus, diabetes mellitus, hypertension, and obesity can lead to the occurrence and advancement of EC [ 9 , 10 , 11 ]. Unlike the aforementioned pathologies, the percentage of malignant pathologies of the endometrium and their impact on fertility are still unknown due to the lack of reports based on large groups of patients [ 12 ]. EC diagnosed in women under 40 years old is usually a very well-differentiated focal endometrioid tumor, restricted in the endometrium or with minimal myometrial invasion, with a high expression of estrogen and progesterone receptors.…”

Section: Introductionmentioning

confidence: 99%

Landscape of Endometrial Cancer: Molecular Mechanisms, Biomarkers, and Target Therapy

Bostan,

Mihaila,

Roman

et al. 2024

Cancers

View full text Add to dashboard Cite

Endometrial cancer is one the most prevalent gynecological cancers and, unfortunately, has a poor prognosis due to low response rates to traditional treatments. However, the progress in molecular biology and understanding the genetic mechanisms involved in tumor processes offers valuable information that has led to the current classification that describes four molecular subtypes of endometrial cancer. This review focuses on the molecular mechanisms involved in the pathogenesis of endometrial cancers, such as genetic mutations, defects in the DNA mismatch repair pathway, epigenetic changes, or dysregulation in angiogenic or hormonal signaling pathways. The preclinical genomic and molecular investigations presented allowed for the identification of some molecules that could be used as biomarkers to diagnose, predict, and monitor the progression of endometrial cancer. Besides the therapies known in clinical practice, targeted therapy is described as a new cancer treatment that involves identifying specific molecular targets in tumor cells. By selectively inhibiting these targets, key signaling pathways involved in cancer progression can be disrupted while normal cells are protected. The connection between molecular biomarkers and targeted therapy is vital in the fight against cancer. Ongoing research and clinical trials are exploring the use of standard therapy agents in combination with other treatment strategies like immunotherapy and anti-angiogenesis therapy to improve outcomes and personalize treatment for patients with endometrial cancer. This approach has the potential to transform the management of cancer patients. In conclusion, enhancing molecular tools is essential for stratifying the risk and guiding surgery, adjuvant therapy, and cancer treatment for women with endometrial cancer. In addition, the information from this review may have an essential value in the personalized therapy approach for endometrial cancer to improve the patient’s life.

show abstract